423 related articles for article (PubMed ID: 30787177)
1. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.
Maity G; Ghosh A; Gupta V; Haque I; Sarkar S; Das A; Dhar K; Bhavanasi S; Gunewardena SS; Von Hoff DD; Mallik S; Kambhampati S; Banerjee SK; Banerjee S
Mol Cancer Ther; 2019 Apr; 18(4):788-800. PubMed ID: 30787177
[TBL] [Abstract][Full Text] [Related]
2. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
3. The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling.
Maity G; Haque I; Ghosh A; Dhar G; Gupta V; Sarkar S; Azeem I; McGregor D; Choudhary A; Campbell DR; Kambhampati S; Banerjee SK; Banerjee S
J Biol Chem; 2018 Mar; 293(12):4334-4349. PubMed ID: 29414775
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
5. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway.
Pu N; Gao S; Yin H; Li JA; Wu W; Fang Y; Zhang L; Rong Y; Xu X; Wang D; Kuang T; Jin D; Yu J; Lou W
Cancer Lett; 2019 Sep; 460():42-53. PubMed ID: 31233838
[TBL] [Abstract][Full Text] [Related]
6. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z
J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745
[TBL] [Abstract][Full Text] [Related]
7. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
8. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
[TBL] [Abstract][Full Text] [Related]
9. Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer.
Dash S; Ueda T; Komuro A; Honda M; Sugisawa R; Okada H
Cell Death Dis; 2024 Feb; 15(2):131. PubMed ID: 38346958
[TBL] [Abstract][Full Text] [Related]
10. MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
Dash S; Ueda T; Komuro A; Amano H; Honda M; Kawazu M; Okada H
Mol Cancer Res; 2023 May; 21(5):444-457. PubMed ID: 36757299
[TBL] [Abstract][Full Text] [Related]
11. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
[TBL] [Abstract][Full Text] [Related]
12. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
14. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
[TBL] [Abstract][Full Text] [Related]
15. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
Duan W; Chen K; Jiang Z; Chen X; Sun L; Li J; Lei J; Xu Q; Ma J; Li X; Han L; Wang Z; Wu Z; Wang F; Wu E; Ma Q; Ma Z
Cancer Lett; 2017 Jan; 385():225-233. PubMed ID: 27773749
[TBL] [Abstract][Full Text] [Related]
16. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
[TBL] [Abstract][Full Text] [Related]
17. Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis.
Haque I; Mehta S; Majumder M; Dhar K; De A; McGregor D; Van Veldhuizen PJ; Banerjee SK; Banerjee S
Mol Cancer; 2011 Jan; 10():8. PubMed ID: 21232118
[TBL] [Abstract][Full Text] [Related]
18. Ginsenoside Rg3 suppresses the growth of gemcitabine-resistant pancreatic cancer cells by upregulating lncRNA-CASC2 and activating PTEN signaling.
Zou J; Su H; Zou C; Liang X; Fei Z
J Biochem Mol Toxicol; 2020 Jun; 34(6):e22480. PubMed ID: 32104955
[TBL] [Abstract][Full Text] [Related]
19. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
[TBL] [Abstract][Full Text] [Related]
20. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.
Park JK; Kim Y; Kim H; Jeon J; Kim TW; Park JH; Hwnag YI; Lee WJ; Kang JS
Oncotarget; 2016 Nov; 7(46):75081-75093. PubMed ID: 27655706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
